Dengue is a mosquito-borne infection that in recent decades has become a major international public health concern. Dengue is caused by four distinct, closely related, enveloped RNA viruses which are members of the flavivirus group. The dengue viruses, are the most widespread arthropod-borne viruses (arboviruses).
Dengue fever is a febrile illness that affects infants, young children and adults. Symptoms range from a mild fever, to incapacitating high fever, with severe headache, pain behind the eyes, muscle and joint pain, and rash. More severe forms of the disease are dengue haemorrhagic fever (DHF) which is a potentially lethal complication with fever, abdominal pain, vomiting and bleeding which affects mainly children and dengue shock syndrome (DSS) where a very low blood pressure can cause organ dysfunction.
Dengue vaccine standardization
Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated) were adopted by ECBS in 2011.
Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Annex 2, Technical Report Series No. 979
No WHO reference materials for dengue vaccines are currently available.
WHO Working Group on Technical Specifications for Manufacture and Evaluation of Dengue Vaccines, Geneva, Switzerland, 11-12 May 2009
Meeting of the WHO Task Force on Clinical Trials of Dengue Vaccines, Bangkok, Thailand, October 2004
Report of the Steering Committee on Dengue and other Flaviviruses Vaccines, WHO, Geneva, April 2004
- WHO dengue fact sheet
- WHO dengue topic page
- Special Programme for Research and Training in tropical diseases
- Epidemic and endemic alert and response
- International travel and health